Resumen de acción IQV
IQVIA Holdings Inc. se dedica al suministro de análisis avanzados, soluciones tecnológicas y servicios de investigación clínica a la industria de las ciencias de la vida en América, Europa, África y Asia-Pacífico.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de IQVIA Holdings Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$234.88 |
| 52 Week High | US$261.73 |
| 52 Week Low | US$167.42 |
| Beta | 1.52 |
| 1 Month Change | -7.12% |
| 3 Month Change | 8.20% |
| 1 Year Change | 23.62% |
| 3 Year Change | 0.39% |
| 5 Year Change | 69.26% |
| Change since IPO | 457.78% |
Noticias y actualizaciones recientes
Is It Time To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)?
Apr 24
Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14Recent updates
Is It Time To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)?
Apr 24Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14IQVIA Holdings: Strong Q4 Results Suggest A Bullish 2024
Feb 22Is IQVIA Holdings Inc. (NYSE:IQV) Trading At A 29% Discount?
Jan 23Market Participants Recognise IQVIA Holdings Inc.'s (NYSE:IQV) Earnings
Dec 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Dec 08Should You Investigate IQVIA Holdings Inc. (NYSE:IQV) At US$205?
Nov 23IQVIA Q3: TAS Segment Remains The Problem Child
Nov 21IQVIA: I Would Stay Away Until Debt Issues Are Resolved
Nov 12Is There An Opportunity With IQVIA Holdings Inc.'s (NYSE:IQV) 32% Undervaluation?
Oct 08IQVIA: Stock To Remain Rangebound As I Expect Weak Numbers In The Near Term
Sep 07Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
Sep 04Why IQVIA Holdings Inc. (NYSE:IQV) Could Be Worth Watching
Aug 11IQVIA Holdings Q2: Breaking Ground And Beating Expectations
Aug 03IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 43% Above Its Share Price
Jun 27IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet
Jun 05IQVIA Holdings: A Possible Beat And Raise Scenario In The Works
May 23What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
May 04A Look At The Fair Value Of IQVIA Holdings Inc. (NYSE:IQV)
Mar 19Does IQVIA Holdings (NYSE:IQV) Have A Healthy Balance Sheet?
Mar 05Here's Why We Think IQVIA Holdings (NYSE:IQV) Might Deserve Your Attention Today
Feb 12IQVIA Q4 2022 Earnings Preview
Feb 09When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Jan 29IQVIA Holdings: Premium Valuation Is Justified For An Industry Leader
Jan 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Nov 09IQVIA Holdings Sees Digital Opportunities, But Debt Drags Growth
Nov 02IQVIA Q3 2022 Earnings Preview
Oct 25Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Oct 02IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)
Sep 19With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 22GSK, Iqvia launch Vaccine Track platform to highlight vaccine trends publicly in US
Aug 11We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Aug 08IQVIA: Resiliency And Quality Never Left, Q2 Earnings Evidence The Same
Jul 28Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 48%?
Jul 26IQVIA Non-GAAP EPS of $2.44 beats by $0.06, revenue of $3.54B beats by $50M, raises FY22 guidance
Jul 21IQVIA A Smart Choice In A High-Inflation Environment
Apr 29When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Mar 28Here's Why We Think IQVIA Holdings (NYSE:IQV) Is Well Worth Watching
Mar 01IQVIA: Intelligent Healthcare Solutions For A Growing Market
Feb 19IQVIA Holdings (NYSE:IQV) Seems To Use Debt Quite Sensibly
Feb 17Is Now An Opportune Moment To Examine IQVIA Holdings Inc. (NYSE:IQV)?
Dec 16Rentabilidad de los accionistas
| IQV | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 1.5% | 3.2% | 2.0% |
| 1Y | 23.6% | 1.0% | 22.3% |
Rentabilidad vs. Industria: IQV superó al sector US Life Sciences , que obtuvo un rendimiento del 1% el año pasado.
Rentabilidad vs. Mercado: IQV superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.
Volatilidad de los precios
| IQV volatility | |
|---|---|
| IQV Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: IQV no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IQV (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 87,000 | Ari Bousbib | www.iqvia.com |
IQVIA Holdings Inc. se dedica al suministro de análisis avanzados, soluciones tecnológicas y servicios de investigación clínica a la industria de las ciencias de la vida en América, Europa, África y Asia-Pacífico. Opera a través de tres segmentos: Soluciones tecnológicas y analíticas, Soluciones de investigación y desarrollo, y Ventas por contrato y soluciones médicas. El segmento de Soluciones Tecnológicas y Analíticas ofrece una gama de aplicaciones basadas en la nube y servicios de implantación relacionados; soluciones del mundo real que permiten a los clientes del sector de las ciencias de la vida y los proveedores generar y difundir pruebas, que informan la toma de decisiones sanitarias y mejoran los resultados de los pacientes; y servicios de consultoría estratégica y de implantación, como análisis avanzados y servicios de externalización de procesos comerciales.
Resumen de fundamentos de IQVIA Holdings Inc.
| Estadísticas fundamentales de IQV | |
|---|---|
| Capitalización bursátil | US$42.75b |
| Beneficios(TTM) | US$1.36b |
| Ingresos (TTM) | US$14.98b |
31.5x
Ratio precio-beneficio (PE)2.9x
Ratio precio-ventas (PS)¿Está IQV sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de IQV | |
|---|---|
| Ingresos | US$14.98b |
| Coste de los ingresos | US$9.75b |
| Beneficio bruto | US$5.24b |
| Otros gastos | US$3.88b |
| Beneficios | US$1.36b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 02, 2024
| Beneficios por acción (BPA) | 7.46 |
| Margen bruto | 34.96% |
| Margen de beneficio neto | 9.06% |
| Ratio deuda/patrimonio | 224.5% |
¿Cómo se ha desempeñado IQV a largo plazo?
Ver rendimiento histórico y comparativa